Analysis of the Incidence of Expression of Tumor Antigens and Tumor Marker in Cancer Tissue From Asian Patients With Hepatocellular Carcinoma and Evaluation of Prognostic Significance of These Tumor Antigens.
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Hepatocellular Carcinoma
Both
Hepatocellular Carcinoma
Trial Information
Analysis of the Incidence of Expression of Tumor Antigens and Tumor Marker in Cancer Tissue From Asian Patients With Hepatocellular Carcinoma and Evaluation of Prognostic Significance of These Tumor Antigens.
Inclusion Criteria:
- The patient has pathologically proven hepatocellular carcinoma (any stage)
- All the data required are available from patient's records
Exclusion Criteria:
N/A
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Retrospective
Outcome Measure:
The proportion of hepatocellular carcinoma patients whose tumor tissue expresses specific tumor antigens.
Outcome Time Frame:
At the time of analysis
Safety Issue:
No
Principal Investigator
GSK Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
GlaxoSmithKline
Authority:
Thailand: Maharajnakorn Chiangmai Hospital: Research Ethics Committee, Faculty of Medicine, Chiang Mai University
Study ID:
111726
NCT ID:
NCT00911196
Start Date:
November 2008
Completion Date:
March 2009
Related Keywords:
- Hepatocellular Carcinoma
- Prognosis
- Markers
- Expression analysis
- Hepatocellular carcinoma
- Carcinoma
- Carcinoma, Hepatocellular
Name | Location |
|---|
